Ikääntyvän miehen seksuaalisuus ja sen häiriöt

Ikääntyvän miehen seksuaalinen toimintakyky heikkenee mutta vähemmän kuin on oletettu. Myös seksuaalinen halu säilyy pitkään. Tavallisimmat häiriöt ovat erektiokyvyn heikkeneminen ja ejakulaation häiriöt. Virtsaamisoireilla ja seksuaalitoimintojen häiriöillä on vahva yhteys toisiinsa. Osa miehistä saa apua niihin häiriöihin samalla, kun hoidetaan eturauhasen liikakasvun aiheuttamia virtsaamisoireita. Erektiohäiriö voi olla ensimmäinen oire sydän- ja verisuonitaudista, minkä vuoksi sen riskitekijöiden kartoittaminen ja tarvittaessa myös hoitaminen ovat tärkeitä. Ejakulaatiohäiriön syynä saattavat olla myös lääkkeet, kuten selektiivisesti serotoniinin takaisinottoa estävät masennuslääkkeet tai eturauhasen liikakasvun hoitoon käytetyt lääkkeet, etenkin alfasalpaaja tamsulosiini. Jos iäkäs mies haluaa seksuaalihäiriöönsä hoitoa, hänelle tulee tarjota yksilöllisesti parhaiten sopivaa hoitomuotoa. English summary: Sexuality and sexual disorders of aging man Functional ability of an aging man decreases less than presumed, and sexual desire remains for long. The most common disturbances include lessened ability for erection and ejaculatory disturbances. Some men will be helped for their sexual disturbances in connection with the treatment of urinary symptoms caused by benign prostatic hyperplasia. Erectile dysfunction may be the initial symptom of cardiovascular disease. Erectile dysfunction may also be caused by medication used by the patient. If an aged man wants therapy for his sexual disorder, he should be individually provided with the most appropriate treatment form

Ikääntyvän miehen seksuaalisuus ja sen häiriöt

Ikääntyvän miehen seksuaalinen toimintakyky heikkenee mutta vähemmän kuin on oletettu. Myös seksuaalinen halu säilyy pitkään. Tavallisimmat häiriöt ovat erektiokyvyn heikkeneminen ja ejakulaation häiriöt. Virtsaamisoireilla ja seksuaalitoimintojen häiriöillä on vahva yhteys toisiinsa. Osa miehistä saa apua niihin häiriöihin samalla, kun hoidetaan eturauhasen liikakasvun aiheuttamia virtsaamisoireita. Erektiohäiriö voi olla ensimmäinen oire sydän- ja verisuonitaudista, minkä vuoksi sen riskitekijöiden kartoittaminen ja tarvittaessa myös hoitaminen ovat tärkeitä. Ejakulaatiohäiriön syynä saattavat olla myös lääkkeet, kuten selektiivisesti serotoniinin takaisinottoa estävät masennuslääkkeet tai eturauhasen liikakasvun hoitoon käytetyt lääkkeet, etenkin alfasalpaaja tamsulosiini. Jos iäkäs mies haluaa seksuaalihäiriöönsä hoitoa, hänelle tulee tarjota yksilöllisesti parhaiten sopivaa hoitomuotoa. English summary: Sexuality and sexual disorders of aging man Functional ability of an aging man decreases less than presumed, and sexual desire remains for long. The most common disturbances include lessened ability for erection and ejaculatory disturbances. Some men will be helped for their sexual disturbances in connection with the treatment of urinary symptoms caused by benign prostatic hyperplasia. Erectile dysfunction may be the initial symptom of cardiovascular disease. Erectile dysfunction may also be caused by medication used by the patient. If an aged man wants therapy for his sexual disorder, he should be individually provided with the most appropriate treatment form

Human factors and ergonomics considerations in the industrial metaverse

The industrial metaverse is a new and emerging topic in smart manufacturing, extending the previous Industry 4.0 concept of cyber-physical systems in manufacturing. The trend is in its early phase, and the definition of the concept is still forming. The goal of this paper is to study the industrial metaverse from the human factors and ergonomics (HF/E) point of view to ensure that the related design and development efforts have a holistic approach. Three industrial metaverse work scenarios were created and assessed from the HF/E point of view. Based on the scenario analysis, new opportunities and challenges were identified related to user experience, usability, usefulness, user acceptance, ergonomics, safety and ethics. This paper is one of the first to start the HF/E discussion related to the metaverse, and its findings can be used both by the research community and the industry when stepping into the era of the industrial metaverse.</p

Is the prevalence of overactive bladder overestimated? : A population-based study in Finland

Background. In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and exclusions. Methodology/Principal Findings. The aim of the study was to assess the age-standardized prevalence of overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology. In 2003-2004, a questionnaire was mailed to 6,000 randomly selected Finns aged 18-79 years who were identified from the Finnish Population Register Centre. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6% [CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder. Conclusions/Significance. Our results indicate a prevalence of overactive bladder as low as 8% suggesting that, in previous studies, occurrence has been overestimated due to vague criteria and selected study populations regarding age distribution and low participation.Background. In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and exclusions. Methodology/Principal Findings. The aim of the study was to assess the age-standardized prevalence of overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology. In 2003-2004, a questionnaire was mailed to 6,000 randomly selected Finns aged 18-79 years who were identified from the Finnish Population Register Centre. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6% [CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder. Conclusions/Significance. Our results indicate a prevalence of overactive bladder as low as 8% suggesting that, in previous studies, occurrence has been overestimated due to vague criteria and selected study populations regarding age distribution and low participation.Background. In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and exclusions. Methodology/Principal Findings. The aim of the study was to assess the age-standardized prevalence of overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology. In 2003-2004, a questionnaire was mailed to 6,000 randomly selected Finns aged 18-79 years who were identified from the Finnish Population Register Centre. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6% [CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder. Conclusions/Significance. Our results indicate a prevalence of overactive bladder as low as 8% suggesting that, in previous studies, occurrence has been overestimated due to vague criteria and selected study populations regarding age distribution and low participation.Peer reviewe

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level

Statins have been associated with a decreased cancer mortality. However, cholesterol level as such may modify the risk of cancer death. To clarify the complex interplay between statins, cholesterol level, and cancer mortality, we conducted a comprehensive analysis to separate the effects of cholesterol level and statin medication on cancer mortality. Our study population consisted of 16,924 men participating in the Finnish Randomized Study of Screening for Prostate Cancer with at least one cholesterol measurement during follow-up (1996–2017). Cox proportional regression was used to estimate hazard ratios. In total, 1699 cancer deaths were observed during the median follow-up of 19 years. When statins’ association with the risk of cancer death was estimated without adjustment for cholesterol level, statin use was associated with a lowered cancer mortality (HR 0.87; 95% CI 0.79–0.97) compared to non-users. However, with further adjustment for total cholesterol level, statin use was no longer associated with a lower cancer mortality (HR 1.08; 95% CI 0.97–1.20). Upon stratified analysis, statin use was associated with a decreased cancer mortality only if the total cholesterol level decreased after the initiation of statin use (HR 0.66; 95% CI 0.58–0.76). The inverse association between statin use and cancer mortality is limited to men with a reduction in total cholesterol level after the commencement of statins, i.e., statin use is associated with a lowered cancer mortality only if the total cholesterol level decreases. This suggests that the effect of statin use on cancer mortality relates to the decreased total cholesterol level

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level

Statins have been associated with a decreased cancer mortality. However, cholesterol level as such may modify the risk of cancer death. To clarify the complex interplay between statins, cholesterol level, and cancer mortality, we conducted a comprehensive analysis to separate the effects of cholesterol level and statin medication on cancer mortality. Our study population consisted of 16,924 men participating in the Finnish Randomized Study of Screening for Prostate Cancer with at least one cholesterol measurement during follow-up (1996–2017). Cox proportional regression was used to estimate hazard ratios. In total, 1699 cancer deaths were observed during the median follow-up of 19 years. When statins’ association with the risk of cancer death was estimated without adjustment for cholesterol level, statin use was associated with a lowered cancer mortality (HR 0.87; 95% CI 0.79–0.97) compared to non-users. However, with further adjustment for total cholesterol level, statin use was no longer associated with a lower cancer mortality (HR 1.08; 95% CI 0.97–1.20). Upon stratified analysis, statin use was associated with a decreased cancer mortality only if the total cholesterol level decreased after the initiation of statin use (HR 0.66; 95% CI 0.58–0.76). The inverse association between statin use and cancer mortality is limited to men with a reduction in total cholesterol level after the commencement of statins, i.e., statin use is associated with a lowered cancer mortality only if the total cholesterol level decreases. This suggests that the effect of statin use on cancer mortality relates to the decreased total cholesterol level

P2P TV: Evaluating Content Delivery and User Experience

In this paper, we present findings from empirical studies on end users' experiences of peer-to-peer (P2P) networked television services. To explore the quality of user experience and content consumption in the evolving TV system, we have developed a peer-to-peer social media service prototype, which can be used both with regular home computer networks and on mobile devices, providing users a real pervasive, ambient media experience. Our primary goal is to create an understanding of the factors that shape P2P TV experience as a basis for the future design of NextShare, a peer-to-peer social media service. Through this research, we concluded that P2P technology can provide a reliable mechanism for ingestion of time-based TV program as well as VOD content via the Internet. P2P technology is especially suitable for large media content providers. However, in order to create a real business value out of the service, new, innovative content production models and types need to be developed

Synthesis and Cytotoxicity Evaluation of Spirocyclic Bromotyrosine Clavatadine C Analogs

Marine-originated spirocyclic bromotyrosines are considered as promising scaffolds for new anticancer drugs. In a continuation of our research to develop potent and more selective anticancer compounds, we synthesized a library of 32 spirocyclic clavatadine analogs by replacing the agmatine, i.e., 4-(aminobutyl)guanidine, side chain with different substituents. These compounds were tested for cytotoxicity against skin cancer using the human melanoma cell line (A-375) and normal human skin fibroblast cell line (Hs27). The highest cytotoxicity against the A-375 cell line was observed for dichloro compound 18 (CC50 0.4 ± 0.3 µM, selectivity index (SI) 2). The variation of selectivity ranged from SI 0.4 to reach 2.4 for the pyridin-2-yl derivative 29 and hydrazide analog of 2-picoline 37. The structure–activity relationships of the compounds in respect to cytotoxicity and selectivity toward cancer cell lines are discussed